Tarsus Pharmaceuticals (TARS) Competitors

In the previous week, Tarsus Pharmaceuticals had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 3 mentions for Elanco Animal Health. Tarsus Pharmaceuticals' average media sentiment score of 0.52 beat Elanco Animal Health's score of 0.16 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Elanco Animal Health has a net margin of -3.96% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Elanco Animal Health's return on equity of 8.13% beat Tarsus Pharmaceuticals' return on equity.

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Elanco Animal Health has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Elanco Animal Health presently has a consensus target price of $29.70, suggesting a potential upside of 33.19%. Tarsus Pharmaceuticals has a consensus target price of $100.86, suggesting a potential upside of 37.02%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Elanco Animal Health.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tarsus Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 2 mentions for Dr. Reddy's Laboratories. Tarsus Pharmaceuticals' average media sentiment score of 0.52 beat Dr. Reddy's Laboratories' score of 0.42 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Tarsus Pharmaceuticals' return on equity.

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals currently has a consensus target price of $100.86, indicating a potential upside of 37.02%. Dr. Reddy's Laboratories has a consensus target price of $1,450.00, indicating a potential upside of 11,738.67%. Given Dr. Reddy's Laboratories' higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Tarsus Pharmaceuticals.

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Axsome Therapeutics' net margin of -24.68%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Axsome Therapeutics' return on equity.

Axsome Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $275.84, suggesting a potential upside of 59.47%. Tarsus Pharmaceuticals has a consensus price target of $100.86, suggesting a potential upside of 37.02%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than Tarsus Pharmaceuticals.

Tarsus Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 7 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.52 beat Axsome Therapeutics' score of 0.24 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Crinetics Pharmaceuticals presently has a consensus target price of $83.44, suggesting a potential downside of 1.77%. Tarsus Pharmaceuticals has a consensus target price of $100.86, suggesting a potential upside of 37.02%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Tarsus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 0 mentions for Crinetics Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Tarsus Pharmaceuticals has a net margin of -7.67% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Crinetics Pharmaceuticals' return on equity.